Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/07/23
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7GlobeNewsWire • 08/02/23
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of DirectorsGlobeNewsWire • 07/13/23
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyGlobeNewsWire • 06/30/23
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophyGlobeNewsWire • 06/13/23
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 06/07/23
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11GlobeNewsWire • 05/04/23
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ PlatformGlobeNewsWire • 04/27/23
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceGlobeNewsWire • 03/23/23
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/15/23
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15GlobeNewsWire • 03/08/23
Capricor Therapeutics Receives Clinical Research Forum's 2023 Top Ten Clinical Research Achievement AwardGlobeNewsWire • 03/02/23
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in JapanGlobeNewsWire • 02/16/23
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy PatientsGlobeNewsWire • 01/25/23
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 ProgramGlobeNewsWire • 01/19/23
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome PlatformGlobeNewsWire • 01/12/23
Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/11/23